Jump to content

Parsatuzumab

From Wikipedia, the free encyclopedia
Parsatuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetEGFL7
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6560H10130N1758O2046S46
Molar mass147836.22 g·mol−1

Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.[1]

This drug was developed by Genentech/Roche.[2]

References

[edit]
  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Parsatuzumab, American Medical Association.